VP
Vikram Purohit Morgan Stanley Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Absci
ABSI
$368M
| $2.46 | $5.89 |
139%
upside
| Overweight |
18 Aug ‘25
21 days ago |
|
2
Halozyme
HALO
$8.76B
| $74.93 | $80 |
7%
upside
| Overweight |
18 Aug ‘25
21 days ago |
|
3
Recursion Pharmaceuticals
RXRX
$2.01B
| $4.61 | $5 |
8%
upside
| Equal-Weight |
3 Jul ‘25
2 months ago |
|
4
Ascendis Pharma
ASND
$12.5B
| $205.91 | $250 |
21%
upside
| Overweight |
5 May ‘25
4 months ago |
|
5
Incyte
INCY
$16.9B
| $86.64 | $65 |
25%
downside
| Equal-Weight |
24 Mar ‘25
5 months ago |
|
6
Axsome Therapeutics
AXSM
$6.25B
| $125.17 | $190 |
52%
upside
| Overweight |
27 Feb ‘25
6 months ago |
|
|
ZBIO
7
Zenas BioPharma, Inc. Common Stock
ZBIO
$864M
| $20.51 | $35 |
71%
upside
| Overweight |
11 Dec ‘24
9 months ago |
|
8
Foghorn Therapeutics
FHTX
$326M
| $5.77 | $9 |
56%
upside
| Equal-Weight |
24 Sep ‘24
11 months ago |
|
9
Genmab
GMAB
$16.9B
| $27.54 | $31 |
13%
upside
| Equal-Weight |
11 Sep ‘24
1 year ago |
|
|
ABVX
10
Abivax
ABVX
$6.65B
| $88.03 | $16 |
82%
downside
| Equal-Weight |
11 Apr ‘24
1 year ago |
|
|
CMPS
11
Compass Pathways
CMPS
$493M
| $5.14 | $30 |
484%
upside
| Overweight |
1 Apr ‘24
1 year ago |
|
12
Arcutis Biotherapeutics
ARQT
$2.06B
| $17.15 | $10 |
42%
downside
| Overweight |
13 Nov ‘23
1 year ago |
|
13
Ventyx Biosciences
VTYX
$180M
| $2.52 | $6 |
138%
upside
| Equal-Weight |
7 Nov ‘23
1 year ago |
|
14
Regenxbio
RGNX
$490M
| $9.71 | $42 |
333%
upside
| Overweight |
29 Aug ‘23
2 years ago |
|
15
Tourmaline Bio
TRML
$687M
| $26.74 | $30 |
12%
upside
| Equal-Weight |
23 Feb ‘23
2 years ago |
|
16
Kymera Therapeutics
KYMR
$3.11B
| $43.51 | $41 |
6%
downside
| Equal-Weight |
19 Dec ‘22
2 years ago |
|
17
Instil Bio
TIL
$213M
| $31.50 | $40 |
27%
upside
| Equal-Weight |
12 Dec ‘22
2 years ago |
|
18
ProKidney
PROK
$304M
| $2.25 | $13 |
478%
upside
| Equal-Weight |
10 Nov ‘22
2 years ago |
|
19
Schrodinger
SDGR
$1.41B
| $19.13 | $38 |
99%
upside
| Equal-Weight |
4 Nov ‘22
2 years ago |
|
20
Certara
CERT
$1.69B
| $10.52 | $20 |
90%
upside
| Equal-Weight |
24 Aug ‘22
3 years ago |
|
21
Theravance Biopharma
TBPH
$703M
| $13.95 | $10 |
28%
downside
| Underweight |
25 Jul ‘22
3 years ago |
|
22
TScan Therapeutics
TCRX
$108M
| $1.91 | $22 |
1,052%
upside
| Overweight |
10 Aug ‘21
4 years ago |
|
|
DBVT
23
DBV Technologies
DBVT
$245M
| $8.97 | $20 |
123%
upside
| Equal-Weight |
5 Aug ‘20
5 years ago |
|